The use of PBPK modeling across the pediatric age range using propofol as a case Robin MicheletJan Van BocxlaerAn Vermeulen Original Paper 08 October 2018 Pages: 765 - 785
MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues Silvia Maria LavezziEnrica MezzalanaMonica Simeoni Original Paper 10 November 2018 Pages: 787 - 802
Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure–response modeling of Mayo scores for golimumab in patients with ulcerative colitis Chuanpu HuOmoniyi J. AdedokunHonghui Zhou Original Paper 30 October 2018 Pages: 803 - 816
A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans Konstantinos BiliourisIvan NestorovMirjam N. Trame Original Paper 30 October 2018 Pages: 817 - 827
Modeling the acute effects of exercise on insulin kinetics in type 1 diabetes Spencer FrankAbdulrahman JbailyAndrew J. Szeri Original Paper 03 November 2018 Pages: 829 - 845